Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus carboplatin-based chemotherapy in KRAS wild-type platinum-sensitive recurrent ovarian cancer
2010-018849-59Phase 2Completed
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH. Primary endpoint: Progression-free survival rate at 12 months. Started Jan 2011; status: completed.
02
Drugs
panitumumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2010-018849-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018849-59.